Distraction Osteogenesis (DO) for Craniofacial Deformities

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Coverage Policy

Coverage for distraction osteogenesis is dependent on benefit plan language, may be subject to the provisions of a cosmetic and/or reconstructive surgery benefit and may be governed by state and/or federal mandates. Under many benefit plans, distraction osteogenesis is not covered when performed solely for the purpose of altering appearance or self-esteem or to treat psychological symptomatology or psychosocial complaints related to one’s appearance. Please refer to the applicable benefit plan language to determine the terms, conditions and limitations of coverage.

If coverage for distraction osteogenesis is available, the following conditions of coverage apply.

Distraction osteogenesis is considered medically necessary for the correction of a congenital or acquired craniofacial deformity when BOTH of the following are met:

- ONE of the following craniofacial deformities is present:
  - micrognathia in infants and children that is accompanied by airway obstruction (e.g., Pierre Robin sequence, Treacher Collins or Stickler syndromes)
  - mandibular deficiency that requires lengthening of more than 10 mm
  - lengthening a short mandibular ramus (stretching of the pterygomasseteric sling)
➢ hemifacial microsomia in children with sufficient bone length to anchor an internal or external
distraction device (e.g., Pruzansky Grade I and Ila type mandibular deformity)
➢ syndromic craniosynostosis (e.g., Apert, Crouzon, or Pfeiffer syndromes)

• ONE of the following functional impairments is present:
  ➢ persistent difficulties with mastication and swallowing after causes such as neurological or metabolic
diseases have been excluded
  ➢ malnutrition, significant weight loss, or failure-to-thrive secondary to facial skeletal deformity
  ➢ speech dysfunction directly related to a jaw deformity as determined by a speech and language
pathologist
  ➢ airway obstruction, such as obstructive sleep apnea, documented by polysomnogram where
conservative treatment such as continuous passive airway pressure (CPAP) or an oral appliance
has been attempted and failed despite patient compliance

Distraction osteogenesis is considered NOT medically necessary:

• in preparation for dental implants or orthodontic care
• for the sole purpose of improving individual appearance and profile

Overview

This Coverage Policy addresses distraction osteogenesis for craniofacial deformities.

General Background

According to the American Association of Oral and Maxillofacial Surgeons (AAOMS), distraction osteogenesis
(DO) is a surgical technique in which new bone formation is induced by gradual separation of bony segments by
means of an appliance in conjunction with an osteotomy. The steps and the basic technique of distraction
osteogenesis are:

• Osteotomy phase. An osteotomy or corticotomy with placement of a device either internally or externally
across the bony segment.
• Latency phase. This is a period of time in which the healing process is initiated and callus formation
begins. In most applications, the latency phase is five to seven days – although there are some
maxillofacial situations in which distraction is begun immediately.
• Distraction phase. At this time, the device is activated to create tension across the surgical site. As the
segments are distracted, bone formations begin within the callus. The attendant tissues tend to adapt
well to change, and there is an increase in size of the soft-tissue envelope. This process is termed
distraction histogenesis.
• Consolidation phase. This is the period in which the segments are stabilized in order to allow for
complete maturation of the regenerate bone. There is no activation during this phase.
• Remodeling phase. This phase has been recently described in the literature and, as more long-term
results have been studied, it is apparent that the soft tissues and bone undergo continuing change over
time (AAOMS, 2017).

In general, craniofacial anomalies may be congenital in nature (i.e., present at birth) or acquired, resulting from
trauma, bone growth disturbance, or maxillary and/or mandibular neoplastic or degenerative processes. In these
syndromes, abnormal growth of the jaw bones can lead to severe functional impairments such as airway
obstruction, obstructive sleep apnea, malnutrition, failure to thrive, persistent inability to adequately masticate or
persistent speech dysfunction. The severity of functional impairments correlates to the degree of upper and
lower jaw deformity. Treatment of these conditions has been managed with such interventions as endotracheal
airway support, nasopharyngeal intubation, tracheostomy, appliances that support the soft palate,
vulopalatopharyngoplasty (UPPP), and temporary tongue/lip adhesions.

The most common application site of DO in the craniofacial skeleton is the mandible. It is also used for maxillary
advancement and in the upper face and cranial vault. The primary indications for mandibular DO include severe
bone deficiency, including those with associated malocclusion, masticatory dysfunction, temporomandibular ankylosis, failed costochondral grafts for reconstruction of the mandibular ramus, obstructive apnea, and apertognathia. Congenital syndromes and recognized anomalies associated with these problems can include Treacher-Collins syndrome, Crouzon’s syndrome, Apert’s syndrome, Goldenhar’s syndrome, hemifacial microsomia, Pierre Robin sequence, Stickler syndrome, and orofacial- digital syndrome. Although DO has an important place in mandibular reconstruction, DO is contraindicated in post-radiation bone.

Standard treatment for maxillary and mandibular deficiencies includes craniofacial surgery, orthognathic surgery, dental extraction and orthodontic correction. During craniofacial surgery, osteotomies of the mandible, maxilla, and/or craniofacial bones are performed, and the bones are realigned and maintained in place using plates, screws, and wires. Orthognathic surgery involves only the mandible and maxilla.

The advantages of craniofacial DO are numerous. It allows for skeletal lengthening and advancement in three dimensions. The process is gradual, allowing the skin-soft tissue envelope to adapt to and accommodate the skeletal movement. DO is operatively less involved and requires less operative time (generating less blood loss) than the techniques it is replacing. As a result, it can be done in young children and infants.

Complications specific to the distraction process include: device failure; injuries to various branches of the facial nerve; pin-site infection with external or semi-buried devices; nonunion and premature fusion; complications specific to the osteotomy (e.g., neurovascular or dental injuries); and psychosocial issues related to the recovery (length of treatment time and patient’s physical appearance). DO is more involved postoperatively than standard surgery. The role that the patient or parent assumes with the treatment includes having the distraction devices activated two or more times a day for one or more weeks and frequent office visits to ensure compliance and to allow for equipment adjustments. Initial post distraction outcomes are generally good, however some individuals, such as syndromic patients, respond unpredictably. Relapse, compromised adaptation and defective post-distraction growth cannot always be prevented.

U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration (FDA) approved several Class II distraction devices for use as early as the 1990s. Some of these include the KLS-Martin™ intraoral distractor (manufactured by Karl Leibinger GMBH, Muhleim, Germany), the TRAK™ intraoral mandibular distraction device (manufactured by Medicon, E.G., Tuttlingen, Germany), the Logic™ and the Spectrum™ mid-face distractor (manufactured by Osteomed L.P., Addison, TX) and the ACE™ alveolar distractor (manufactured by ACE Surgical Supply Co., Inc., Brockton, MA).

Literature Review
There is evidence in the published peer-reviewed literature supporting the clinical effectiveness of distraction osteogenesis (DO) as an early alternative to conventional medical and surgical interventions for the treatment of severe craniofacial deformities. DO has been used for patients with a variety of functional impairments. The procedure can be performed alone or in combination with other standard techniques to address these conditions.

Evidence consists of case reports, both prospective and retrospective case series and published reviews. Much of the evidence focuses on repair of congenital deformities rather than acquired. In a majority of clinical studies the populations were small with short-term follow-up; diagnosis among study groups varied, but generally included microsomia, micrognathia, syndromal craniosynostosis, facial bone fractures and other maxillofacial mandibular defects. Follow-up times vary but range from the immediate postoperative period to five years post-surgery; few studies have reported outcomes extending beyond five years. When used early for the correction of hemifacial microsomia in particular, additional distraction procedures may be required.

Depending on individual age and condition, distraction rate, length of treatment and degree of correction vary. Nonetheless, DO has proved useful for correction of severe bone deficiencies and deformities of the mandible. Reported clinical outcomes include prevention of tracheostomies, relieved symptoms of sleep apnea, improvement in mandibular occlusion, improvement in facial asymmetry and retrognathia and improved upper airway status. Many children are likely to require staged procedures, with secondary distraction and/or conventional orthognathic surgery, to be able to control the symmetry in multiple planes. In many cases, simultaneous maxillary-mandibular distraction, in which mandibular distraction device drives the maxillary distraction, can be beneficial.
Professional Societies/Organizations

American Association of Oral and Maxillofacial Surgeons (AAOMS): The AAOMS published a Clinical Condition Statement on Distraction Osteogenesis (2017) and addressed indications for distraction of facial bones stating that the obvious indication for distraction osteogenesis is a situation in which this technique would be more efficient or effective than other available treatment modalities. From that perspective, distraction would be indicated when:

- A degree of improvement unavailable with other techniques would be produced (i.e., a superior result).
- It would produce a similar result in a more cost-effective way. Cost should be considered in a very broad sense, including burden of treatment for the patient and economic factors.

The AAOMS goes on to note that the indications for distraction involving the jaws are limited to conditions in which this technique may be uniquely able to produce significant improvement over more traditional therapy. Examples of these situations are:

- Severe deficiency of either jaw with early correction indicated (e.g., an infant with Pierre Robin with mandibular deficiency so severe that tracheostomy is required and advancement of the mandible is the only way to correct an obstructive situation).
- Severe mandibular deficiency requiring lengthening of the mandible of greater than 10 mm. Growth modification via orthodontics generally produces no more than 5 mm differential growth, and conventional orthognathic procedures become more difficult and less predictable when greater than 8 to 10 mm advancement is needed.
- Need for lengthening of a short mandibular ramus. The nature of distraction osteogenesis is well-suited for stretching of the pterygomasseteric sling, which is not easily overcome by conventional procedures.
- Widening of the maxilla in an adult. Surgically assisted palatal expansion, which is analogous to distraction osteogenesis, has been utilized to overcome this problem for decades with very desirable and stable results.
- Narrow mandible that must be widened. There has been little success in widening the mandible with conventional surgery prior to the advent of distraction. Distraction techniques offer a better way to address this problem.
- Alveolar deficiency. The literature describes grafting techniques for augmenting the alveolar ridge. This is becoming especially popular as an adjunct to implant reconstruction. However, vertical augmentation is often difficult and distraction osteogenesis techniques may offer a means for augmentation of the bony ridge with an increase in soft tissue volume as well.

Coding/Billing Information

Note: 1) This list of codes may not be all-inclusive.
   2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20690</td>
<td>Application of a uniplane (pins or wires in 1 plane), unilateral, external fixation system</td>
</tr>
<tr>
<td>20692</td>
<td>Application of multiplane (pins or wires in more than 1 plane), unilateral, external fixation system (eg, Ilizarov, Monticelli type)</td>
</tr>
<tr>
<td>20693</td>
<td>Adjustment or revision of external fixation system requiring anesthesia (eg, new pin[s] or wire[s] and/or new ring[s] or bar[s])</td>
</tr>
<tr>
<td>20694</td>
<td>Removal, under anesthesia, of external fixation system</td>
</tr>
<tr>
<td>20696</td>
<td>Application of multiplane (pins or wires in more than 1 plane), unilateral, external fixation with stereotactic computer-assisted adjustment (eg, spatial frame), including imaging; initial and subsequent alignment(s), assessment(s), and computation(s) of adjustment schedule(s)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>21100</td>
<td>Application of halo type appliance for maxillofacial fixation, includes removal (separate procedure)</td>
</tr>
<tr>
<td>21110</td>
<td>Application of interdental fixation device for conditions other than fracture or dislocation, includes removal</td>
</tr>
<tr>
<td>21195</td>
<td>Reconstruction of mandibular rami and/or body, sagittal split; without internal rigid fixation</td>
</tr>
</tbody>
</table>


**References**


https://www.accessdata.fda.gov/cdrh_docs/pdf/K981526.pdf


